Abstract
Introduction
Pouchitis is a medical condition associated with an inflammation of the intestinal mucosa of the ileal reservoir [1] . For refractory patients with ulcerative colitis, a total proctocolectomy with an ileoanal anastomosis (J-pouch) is a common surgical procedure [2] [3] [4] [5] [6] . While there is high patient satisfaction after this procedure, 30-60% of these patients experience pouchitis [4] [5] [6] . While the specific cause of pouchitis is unknown, common symptoms include the presence of bloody diarrhea, urgency, dehydration as well as endoscopic evidence of erythema of the mucosal pouch [4] [5] [6] . Despite the lack of a definitive cause, pouchitis may result from toxin release after bacterial dysbiosis, degradation of products, changes in intraluminal pH, low immunoglobulin levels, or other yet undetermined factors [4] [5] [6] [7] [8] . This lack of a clear etiology of pouchitis, may help explain why there is no formal FDA-approved treatment.
Lacking approved therapies, physicians are left to address patient symptoms based upon personal experience and suggestions from other opinion leaders in the management of pouchitis as well as limited clinical data. Antibiotics such as ciprofloxacin and metronidazole are often used as first line therapy [8] . Additional options include systemic and topical steroids, budesonide, topical mesalamine, and VSL#3 [9] . Serum-derived bovine immunoglobin/protein isolate (SBI) is not commonly considered for the management of pouchitis and its associated diarrhea, but SBI has been seen to provide beneficial effects when used in patients with pouchitis or IBD-related conditions where diarrhea is the primary symptom [10] [11] [12] [13] [14] [15] [16] .
The use of medical foods has been shown to have a distinct role in the management of gastrointestinal conditions [17] . SBI is produced and purified from pooled USDA-approved, edible-grade bovine plasma containing ~60% immunoglobulins (>50% IgG, 1% IgA and 5% IgM) along with other proteins and peptides that are similar to those commonly consumed by humans in beef products [18] . EnteraGam ® , a medical food product intended for the dietary management of chronic diarrhea and loose stools, contains 5 g of SBI and 5 g of dextrose with trace amounts of sunflower lecithin per packet [18] . SBI's primary mode of action is the binding of microbial components (i.e., bacterial toxins). This has a downstream effect of reducing inflammatory markers and the restoration of tight junctions between epithelial cells [19] . As a result (Figure 1) , SBI has been shown to help maintain and support barrier function within the gastrointestinal tract in patients with chronic loose and frequent stools [20] [21] [22] . 
Aims
Based upon the growing experience of physicians using medical foods, SBI appears to have potential application for the management of chronic diarrhea associated with pouchitis.
This was considered in this retrospective review of 10 patients, who have utilized prescribed EnteraGam ® (SBI) as part of the management plan for pouchitisassociated diarrhea and the eventual long-term management for the remission of their condition.
Methods
Pouchitis patients who had failed to adequately respond to conventional therapy (antidiarrheal agents, antibiotics, budesonide) were considered for the addition of SBI as part of their standard of care in order to try to manage their pouchitis-associated diarrhea and potentially establish remission. All patients were initially followed for one year and continued to be followed for several additional years as part of the standard of care with SBI.
The retrospective chart review of these 10 patients was based upon an initial assessment of SBI in patients with pouchitis. Given the initial response in these patients, the ongoing review was to determine if they continued to respond over the long-term use of SBI for their pouchitis associated symptoms.
Results
These 10 patients initially lacked a response to conventional therapies for their diarrhea-associated pouchitis symptoms. The individual outline of the history of the patients' pouchitis and efforts to manage the condition included ciprofloxacin, budesonide and/or other typical measures but failed to achieve remission (Table 1 ). For many of these patients, drug treatments including antidiarrheal agents, antibiotics and budesonide helped to manage their pouchitis condition, but they continued to experience pouchitis flares that resulted in severe diarrhea.
Several patients had experienced symptomatic pouchitis flares for many years without satisfactory response to conventional therapies. It was not until the addition of SBI (5 g QD or BID) that 8 of 10 patients achieved clinical, asymptomatic remission of their pouchitis as judged by management of chronic diarrhea and lack of other symptoms along with endoscopic remission documented in 2 of these patients during the first year of therapy (Table 2) . One patient was generally asymptomatic during the first year but had one flare that was resolved with a 10-day course of antibiotics in addition to the SBI. A second patient had significant improvement in the clinical symptoms of pouchitis noting 11 months of remission but was eventually lost-to-follow-up.
All patients continued with SBI therapy with 8 of them using SBI as monotherapy to manage their pouchitis condition. During the second year of treatment, 8 of the 10 patients continued without any flares and 2 more patients were lost-to-follow-up. Of these 2 patients, one had been symptom-free for 11 months at the last report and the second patient had been symptom-free for over a year (Table 2) . Over the long-term, 7 of the original 10 patients were monitored. For the other three, two were noted as lost-to-follow-up during the second year of therapy and one patient eventually moved out of state after being symptom-free and followed for more than 2 years.
Of these remaining 7 patients, 5 patients continued to be well managed on SBI therapy for pouchitis-associated diarrhea with three patients reporting no flares for over 4 years. One patient was treated for over 5 years and had no significant reports of flares over the long-term. One patient was treated for over 3 years without any reports of flares. The 2 remaining patients both reported at least 2 flares during the long-term period. One patient had been treated for over three years during which time two flares were reported. Budesonide was added to the SBI therapy for 14 days and both times the flares resolved.
In the second patient treated for over 4 years, there were reported a few flares generally lasting 2-3 days. Ciprofloxacin was added to the therapy during which the flares resolved. Overall during this long-term review of patients, pouchitis symptom improvements were noted within 2 to 3 weeks of therapy initiation for 8 of 10 patients. As such, maintenance therapy of SBI (5 g QD or BID) for chronic diarrhea has allowed 8 of 10 patients to continue remission for more than 2 years. Three patients were lost-to-follow over time.
Of the remaining 7 patients, there were no issues in 5 of 7 patients and 2 of 7 required an occasionally adjunctive drug therapy to help manage a few minor flares. Flares were generally mild and limited. Of these 7 patients, one was treated for over 5 years without a flare.
Three patients were treated for over 4 years with only one having an occasional mild flare which required the addition of a short-term antibiotic treatment. Two patients were treated for over 3 years with one patient reporting 2 flares during the time period. Six of 7 patients continued SBI therapy and one patient discontinued all therapy for their pouchitis and continues to be symptom free. 
Discussion
Pouchitis is a challenging condition for patients who have gone through the surgical procedure establishing the J-pouch. Nearly 30-60% will experience symptomatic flares within the first year. Without an approved therapy, physicians have utilized a variety of therapeutic agents to help manage the symptoms associated with pouchitis.
These conventional therapies do not provide a satisfactory response and many patients experience repeated flares in their symptoms. For these 10 patients evaluated for over 3 years and one patient for as long as 5 years, the addition of SBI provided the necessary support to manage chronic diarrhea associated with pouchitis when conventional therapy failed to achieve remission.
It was not until the addition of SBI that 10 of 10 patients reported clinical improvement within the first year of therapy with 8 of 10 achieving clinical, asymptomatic remission. Nearly all (8 of 10) patients-maintained remission on SBI during the second year with two patients being lost to follow-up. One patient moved out of state after 2 years on therapy without any reported flares.
Of the remaining patients, 5 of 7 continued to be asymptomatic for as long as 3-5 years and 2 of 7 patients had some limited pouchitis flares that were resolved with adjunctive drug therapy. SBI monotherapy was the standard course of care in 4 of 7 patients with one patient being removed from all therapies and two patients requiring minimal adjunctive drug therapy during a flare.
Conclusion
Unlike common dietary proteins, microbial binding capacity provided by SBI is thought to lead to a cascade of effects: minimizing immune activation, reducing proinflammatory cytokines, and restoring tight junction barrier function. This mechanism of SBI though these actions may provide the necessary effect that potentially removes the trigger for the inflammatory flares in pouchitis patients resulting in diarrheal symptoms thus allowing many patients to achieve not only clinical remission but also endoscopic and histological remission.
The use of medical foods continues to find application within the management of gastrointestinal disorders. SBI may be a valuable option to support the long-term management of chronic diarrhea in pouchitis patients, especially given the lack of any formal approved therapy for pouchitis itself. While pouchitis itself is not currently part of the labeling for SBI (EnteraGam ® ), it is labelled for dietary management of chronic diarrhea and loose stools that is often associated with pouchitis and pouchitis flares.
As such, the use of SBI in this patient population may be warranted to manage diarrhea associated with pouchitis and pouchitis flares. This assessment in 10 pouchitis patients supports the important role of SBI in the initial and long-term diarrheal management of patients with pouchitis.
